Introduction
Epilepsy is one of the most common serious chronic brain diseases with an estimated prevalence of 4-10 cases/1000 individuals worldwide [1, 2] . In Europe, approximately 6 million people suffer from active epilepsy according to the WHO report published in 2010 [3] . It has been estimated that 40-50% of people with epilepsy require a combination of antiepileptic drugs (AEDs) to achieve remission [4, 5] and that 15-25% of people with epilepsy have drug-resistant epilepsy [6, 7] . Approximately 36,000-48,000 persons would suffer from drug-resistant focal epilepsy in France [8] .
The high prevalence of epilepsy and its consequences in terms of social handicap [9] and impaired quality of life [10, 11] result in high burden both for individuals and society [3, 12, 13] . In Europe, the estimates of costs associated to epilepsy vary from s13.8 billion/year in 2010 [14] to s20 billion/year [3] .
In order to improve management of these patients, a working group of the International League Against Epilepsy (ILAE) established a consensus definition of drug-resistant epilepsy in 2009 (2009 ILAE Task Force) [15] .
Despite its high burden, studies on the costs of epilepsy are sparse. The objectives of this study were to describe the direct costs associated with the management of adults with focal epilepsy treated with a combination of AEDs in France and to estimate the supplementary costs related to AED treatment resistance as defined by the 2009 ILAE criteria [15] .
Methods

Study design
ESPERA was a multicentre, observational, cross-sectional study. Data were collected retrospectively for the 12 months preceding inclusion, with the exception of data on disease history and treatment, which were collected for the entire disease course.
Investigators and patients
A sample of 880 neurologists was randomly selected from a nationally representative listing of neurologists in France and invited to participate in the study. In addition, we invited specifically 321 neurologists (not included in the first sample) who were members of the French League against Epilepsy (LFCE). Overall, 71 (6%) of the selected neurologists accepted to participate (3.4% of the randomly selected neurologists and 12.8% of those specifically invited).
Each participating neurologist was asked to enrol prospectively from 6 to 9 consecutive patients meeting the inclusion criteria. Were eligible all adults (age ! 18-years) with focal epilepsy treated with a combination of !2 AEDs and who gave a written informed consent. Patients treated with a combination of AEDs including a benzodiazepine were eligible if this AED was prescribed over the long-term. Patients participating in a clinical trial or hospitalised at the time of the study were not eligible. Among enrolled patients, one out of 3 had to be drug-resistant epilepsy patients. This proportion was imposed by the protocol to ensure that a sufficient number of patients with drug-resistant epilepsy would be included. Each investigator was also asked to fill out a register recording the main clinical characteristics of all consecutive adult patients, treated or not, seen in consultation for focal epilepsy during the inclusion period. This register was used to perform further statistical adjustment intended to obtain the true distribution of patients according to AEDs responsiveness.
Data collection
At inclusion, investigators completed a questionnaire for each patient. This documented socio-demographic, administrative and medical data including history of epilepsy, frequency and type of seizures, aetiology, comorbidities and all data relating to healthcare use: AEDs received since the diagnosis of epilepsy, duration, dose regimens and compliance, consultations, hospitalisations, additional tests (laboratory tests, EEG, X-ray, MRI, CT scan, etc.) and home care. All items of medical resources consumption over the last year were collected by the investigators based on their files and the interview of their patients. The study was designed to collect all information required during the inclusion visit.
Classification according to treatment responsiveness
Investigators were asked to define the AED responsiveness status of each enrolled patient according to the 2009 ILAE criteria [15] . Patients were then classified as having drug resistant epilepsy (''drug-resistant'' patients), drug-responsive epilepsy (''drug-responsive'' patients) or undefined drug responsiveness (''undefined'' patients). Drug resistant epilepsy was defined as failure to achieve sustained seizure freedom, despite adequate trials of two tolerated and appropriately chosen and used AED schedules whether as monotherapies or in combination. Drug responsive epilepsy was defined as epilepsy, in which the patient receiving the current AED treatment regimen, has been seizure free for a minimum of three times the longest interseizure interval (experienced over the year preceding the initiation of the current treatment) or for 12 months, whichever is longer [15] .
The classifications established by investigators were subsequently reviewed by two epileptologists from the study scientific committee according to modalities previously described [16] . All results presented here reflect the classifications validated by these experts.
Source of unit costs and estimation of costs
Our study principally evaluated the direct medical costs of epilepsy. Healthcare resource use included consultations, hospitalisations, laboratory tests, other additional tests (EEG, imaging, etc.) and AED prescription. Direct non-medical costs were limited to payments to salaried caregivers. Valuation was carried out from a societal perspective. The annual cost of care was calculated for each patient by multiplying the volume of resources used during the 12 months preceding inclusion by the unit cost of each item concerned. The mean annual direct epilepsy-related cost per patient, expressed in Euros (2010), was then calculated. Table 1 lists the principal unit costs used and their source. The unit costs of outpatient care services were estimated using current national tariffs and fees for service fixed by the French health authorities. The unit costs of AEDs were obtained from the Dictionnaire Français des Me´dicaments (VIDAL 2010) [17] which provides the current prices of drugs. Costs of AED treatments were then estimated by multiplying the unit cost by the daily dose (after titration if any) and duration of treatment. Unit costs of hospitalisations for each Diagnosis Related Group (DRG) were obtained from the 2008 Etude Nationale des Coûts à Me´thodologie Commune (ENCC) [18] . This study aggregates unit costs from the accounting system of a panel of French public and private hospitals. In absence of hourly tariffs for salaried caregivers in France, home care cost was estimated from the mean cost supplied by French homecare providers. 
Statistical analysis
In order to adjust for sampling bias, the data were weighted by: (i) the number of patients per year treated by the investigator for focal epilepsy, (ii) the proportion of drug-resistant patients among adult patients treated for focal epilepsy by the investigator and (iii) the annual frequency of consultations with the investigator for each patient.
Patient or disease characteristics that could have an impact on the cost of management were compared by bivariate analysis. These included AEDs responsiveness, seizure frequency, aetiology, type of medical practice and gender. As the number of patients with undefined drug responsiveness at inclusion was relatively small, these patients were excluded from the comparative analyses.
The significance of the differences observed was determined using the Chi square test (or Fisher's exact test when the theoretical values were <5) for categorical variables, and Student's t-test (or Wilcoxon test if a normal distribution was not verified) for continuous variables. The level of significance was fixed at 5%. All analyses were performed using SAS 1 version 9.2 (North Carolina, USA).
Results
Between June and October 2010, 428 patients were enrolled. Among them, 23 were secondarily excluded because they did not meet the inclusion criteria and/or the investigator did not fill out the requested register about all patients visiting him during the inclusion period. The analysis was finally performed on 405 patients enrolled by 71 participating neurologists (mean: 6 patients/investigator). Sixty-one percent of neurologists were exclusively hospital-based, 29% worked exclusively in community practice and 10% in both sectors (Fig. 1) .
According to the 2009 ILAE criteria and after experts revision, 70.6% (286/405) of the patients were classified as drug-resistant, 22 .4% (n = 91) were drug-responsive and 7.0% (n = 28) had an undefined AED responsiveness status.
Socio-demographic and clinical characteristics
The socio-demographic characteristics of the enrolled patients are shown in Table 2 . The mean age was 42.7 years (range: 18-88) and the gender ratio (m/f) was 0.98. In patients aged 18-65 years, almost one-quarter (24.5%) were not working because of their epilepsy. This proportion was nearly two times higher in drugresistant than in drug-responsive patients (29.4% vs. 13.0%, p = 0.0002). Table 3 shows the main characteristics of epilepsy in the studied population. The disease started an average of 25 years before inclusion and the mean age at first seizure was 17.7 years. Epilepsy had a known cause in 64.0% of cases. Complex focal seizures were the predominant type of seizure (78% of patients). Just over one-half of patients (52%) had at least one seizure/month at inclusion and 27% of patients had at least one seizure/week. Only 26% of patients had experienced no seizure during the 12 months prior to inclusion. Table 4 presents the rates of utilisation of healthcare resources and home care over the 12 months prior to inclusion. With the exception of consultations with a general practitioner (more frequent among drug-responsive patients) and number of hours of home care received (which did not differ between the groups), use of all healthcare resources appeared to be significantly higher in drug-resistant than in drug-responsive patients. Compared to drug-responsive patients, drug-resistant patients had consulted their neurologist more often (2.9 times vs. 1.9 times, p < 0.0001) and the proportion consulting another specialist or having undergone laboratory tests or other additional exams (EEG, imaging tests, etc.) for their epilepsy was nearly twofold higher. Moreover, while 23% of drug-resistant patients had required emergency services at least once during the last year, this was the case for none of drug-responsive patients. Finally, hospitalisation due to epilepsy was ten times more common in drug-resistant patients (p < 0.0001). Overall, 18% of patients were hospitalised because of their epilepsy (1.4 times on average). Of the 104 hospitalisations that took place, the duration of stay was <24 h in 16% of cases (mean stay duration: 8.8 days; median stay duration: 5 days). At inclusion, 49% of patients were receiving bitherapy, 33% tritherapy and 18% were taking four AEDs (14%) or more (4%), with patients receiving an average of 2.7 AEDs. At inclusion, 82% of drugresponsive patients were receiving bitherapy, while this proportion was only 39% in drug-resistant patients (p < 0.0001). Over the twelve months preceding inclusion, the most frequently prescribed drugs were carbamazepine (48% of patients), levetiracetam (45%) and lamotrigine (36%) ( Table 5 ). In all, 213 different drug combinations were prescribed at inclusion. Only 38% of patients were taking one of the nine most frequently prescribed AED combinations (to at least 2% of patients).
Healthcare resource utilisation and antiepileptic treatments
Annual cost of management
The mean total annual direct epilepsy-related cost for all patients was s3850 (AE4112). AEDs (mean annual cost: s2298 AE 1711) constituted the main item of expenditure (60%), followed by hospitalisation (26%) ( Table 6 ). This distribution was found in all sub-groups of patients except for drug-responsive patients and patients managed in a community practice, for whom the second most common items of cost were consultations and home care respectively. For all patients included, the other cost items represented less than 6% of the total mean annual direct epilepsyrelated cost. The mean annual direct epilepsy-related cost was 2.3 times higher in drug-resistant than in drug-responsive patients (s4485 vs. s1926, respectively, p < 0.0001) ( Table 7 ). The mean annual costs of AEDs, additional exams and hospitalisations were, respectively, two, four and thirteen times higher in drug-resistant than in drug-responsive patients (p < 0.0001).
With respect to seizure frequency, the mean annual direct epilepsy-related cost was 2.6 times higher in patients having monthly seizures than in those who had been in remission for at least 12 months (s5043 vs. s1973, respectively, p < 0.0001); a similar difference was found for all items of cost with the exception of home care. This analysis also showed that the mean annual direct cost of drug-resistant epilepsy (s4485) masked important variations in cost related to seizure frequency. This increased from s2985 when this frequency was <4 seizures/year to s6247 when seizures occurred weekly (!4/month) (p < 0.0001). Concerning the context of care, the mean annual direct epilepsy-related cost was nearly twofold higher in outpatients managed by a hospital-based neurologist compared to patients managed by a community-based neurologist (s4041 vs. s2245, respectively, p < 0.0001). Conversely, there was no significant variation in direct costs according to gender or aetiology.
Discussion
According to the new criteria for AED resistance [15] , our study estimated the proportion of drug-resistant epilepsies among adult patients with focal epilepsy treated with combined AEDs, to be 71% in France. This rate of drug resistance appears to be 3-3.5 times higher than estimates in non-selected epilepsy populations (20-25%) [7, 8] . This finding, in a population where 51% of patients were treated with >2 AEDs, is consistent with data in the literature which show that the probability of complete remission after failure of two AEDs is modest, <20% [19, 20] .
Our economic analysis estimated the mean annual direct epilepsy-related cost to be s3850. AEDs were the main direct costs, irrespective of the sub-group of patients considered. These findings, in patients treated by polytherapy and mainly drug-resistant confirm data from previous studies. According to those, the cost of epilepsy and the distribution of items of expenditure vary over the course of the disease [21] . Studies, which included a non-selected epilepsy population, showed that cost was usually highest in the subgroup of newly diagnosed patients [22, 23] . After the period of diagnosis, except in surgical patients, costs tend to vary according to the treatment response [21] . Thus, as in our study, the AEDs represented the main component of the total direct cost in studies limited to patients with drug-resistant or uncontrolled epilepsy [24, 25] or in subgroups of such patients [23] . In our study, the selection of patients treated by polytherapy may explain that the cost of AEDs was also the main contributor in patients with drug responsive epilepsy. The use of newer generation AEDs in patients not adequately controlled with older generation AEDs may increase significantly the drug expenditure [13, 21] . In our study, 92% of drug cost was due to newer generation AEDs. By contrast and despite the observed trend towards an increasing use of newer generation AEDs [13] , the main driver of direct costs remains hospitalisations in some recent studies. This is the case in two studies [26, 27] conducted in non-selected populations with epilepsy, which included newly diagnosed patients or children which are more often hospitalised than adults [22] . In drug-resistant patients, the mean annual direct epilepsyrelated cost was s4485, the two principal items of cost, AEDs and hospitalisations representing 58% and 28% of this cost, respectively. Compared to the mean annual direct cost for drug-responsive patients, drug resistance therefore results in an average supplementary cost of s2560/year/patient. Comparisons with data from other studies are difficult to interpret. The differences observed may result from differences in patient management between countries or in the methodology used (items of cost considered, in particular in the calculation of direct non-medical costs, type of population studied, etc.). No other economic study in adult patients with epilepsy treated with polytherapy has been identified. However, two studies have provided data on the costs associated with the management of adult patients considered to be uncontrolled by treatment or drug-resistant. In these patients, the mean annual direct epilepsy-related cost was estimated as s4040 by Hamer et al. [24] in a 3-month prospective study in Germany in 2003 and s4982
by Sancho et al. [25] in a cross-sectional study in Spain in 2005. In drug-resistant patients, we estimated the mean annual direct epilepsy-related cost as s4263, which falls between the two previous estimates with a similar distribution of the two predominant items of cost in the three countries. AEDs and hospitalisations represented 61% and 30%, respectively, of the mean annual direct epilepsy-related cost in France vs. 59% and 28% in Germany and Spain. Published data do not allow to explain the differences observed between our study and that of Hamer et al. [24] . The small difference in costs observed between France and Spain (in populations with a comparable mean age and disease duration) are mainly due to additional tests and medical consultations which appeared to be more frequent in Spain; for example, over one year, 92% of Spanish patients required emergency services compared with 23% of French patients. Similarly, 93% of patients received at least one structural MRI in Spain compared with 27% in France (all types of MRI and CT scan included). These differences could be a result of the criteria used for the definition of drug-resistance by Sancho et al. [25] which were more restrictive than the 2009 ILAE criteria [15] and may have led to the inclusion of more severe patients in Spain. However, differences in use of additional exams could also be explained by a potential underestimation of these investigations in France. In our study, no additional test was reported in 30% of drugresistant patients. As a conservative hypothesis, these patients were considered not to have undergone any additional test during the study period. This choice could have led to an underestimate of use and therefore the cost of this item of care. However, it should be noted that this item of cost represented only 2-6.8% of the mean annual direct epilepsy-related cost in recent studies that included drug-resistant patients [23] [24] [25] . Seizure frequency is one of the principal determinants of the cost of epilepsy [10, [22] [23] [24] 28] . In our study, the mean annual direct epilepsy-related cost increased significantly with seizure frequency. However, costs were very similar when the total number of experienced seizures varied between 1 and 11/year. The mean annual direct epilepsy-related cost for patients with monthly seizures (s5043) was nearly three times higher than in patients in remission for at least 12 months (s1973). Likewise, in drugresistant patients, large differences in the mean annual direct epilepsy-related cost were observed depending on seizure frequency. The mean supplementary cost associated with drugresistance increased significantly with seizure frequency from s1060/patient/year for <4 seizures/year to s4320 for weekly seizures (!4 seizures/month).
In our study, and in contrast to the observations of Sancho et al. [25] , the mean annual direct epilepsy-related cost also varied with the setting: it was significantly higher for patients managed in hospital than for those managed in community practice although neurologists in community practice and those in hospitals managed a similar proportion of drug-resistant patients. This can be explained by differences in the clinical profiles of these patients, with hospital neurologists tending to see more severe patients, with a higher rate of monthly seizures (57% vs. 35%, p < 0.0001) and of hospitalisations (22% vs. 5%, p = 0.0003) than did neurologists in community practice.
Lastly, the study also confirmed the large diversity of AED combinations prescribed, a feature also observed by Sancho et al. [25] . This large diversity reflects the pragmatic character of therapeutic strategies [1, 29, 30] . It may be explained by the high prevalence of drug-resistance in our population leading to frequent modifications of treatment, by the need for practitioners to adapt treatments to the clinical characteristics of their patients (age, side-effects, comorbidities, etc.) and by the fact that the comparative efficacy of different AED combinations is poorly documented [29, 30] .
Several limitations of this study should be considered in interpreting the results. Firstly, it was carried out on a specific subgroup of patients, namely adults with focal epilepsy treated with polytherapy, which represents the most severe forms of epilepsy in adults [29, 31] . Furthermore, the direct non-medical costs considered in our study were limited to paid home care. They did not take into account the costs of transport or management of side-effects of AED treatment and were therefore underestimated. We also did not estimate the indirect costs of the disease which represent the largest part of the overall cost in many studies [13, 32] and can be as much as 85% of the total cost of epilepsy [33] .
Another limitation of the study is related to the method for collection of medical resources consumption in the previous year. Investigators were asked to collect these data by consulting their medical records during the inclusion visit and to ask patients to complete these data when they were missing from their records. This may have led to an underestimation of costs as the patients may not have recalled all relevant medical consumption in the previous year.
It should also be noted that, since there is no data available on the number of neurologists specialised in the management of epilepsy in France, we cannot confirm that the neurologists in the ESPERA study were representative of those who manage adult focal epilepsy patients on polytherapy in France. It is possible that the ratio of drug-resistant patients imposed by the study protocol resulted in a higher proportion of epileptologists among the participating neurologists than in real life and thus a higher proportion of more severe patients at inclusion. However, the proportion of drug-resistant patients did not differ significantly according to the type of practice or whether the neurologists were epilepsy specialists or not. The proportion of hospital neurologists taking part in the study (61%) was similar to that observed nationally (63%) [34] . Furthermore, 44% of reasons for nonparticipation concerned neurologists who had no patients with epilepsy or few patients on polytherapy. These reasons suggest that the population studied may be considered as representative of adult focal epilepsy patients receiving polytherapy in France.
Conclusion
The direct cost of focal epilepsy in adults treated with a combination of AEDs was estimated to be s3850/patient/year in France. Drug resistance, as defined by the 2009 ILAE criteria, resulted in a mean extra cost of s2560/patient/year, but this extra cost varied significantly with seizure frequency (from s1060 to s4320). Despite the many AED combinations available, the choice of optimal AED combination remains difficult and a large proportion of focal epilepsies in adults treated with polytherapy remain uncontrolled. The recent development of consensual criteria for the definition of drug resistance, intended to facilitate epilepsy research, as well as their implementation, should lead to better guidance in the management of epilepsy patients.
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